Cortexyme has entered into a deal to acquire Novosteo. Once the deal is finalized, the two companies will enter the rare disease space and operate under the name Quince Therapeutics.
The 2022 International Conference on Alzheimer’s and Parkinson’s Disease ended last weekend, but it reported on numerous research studies and insights into the diseases.
(Reuters) - Cortexyme Inc said on Tuesday its experimental oral pill failed to meet the main goals of improving cognitive and functional abilities in .